Ideas and Forecasts on Stocks — Sweden — TradingView

$HNSA , Setup ENTRY : CMP TP1 : 4.08 TP2 : 7.97 TP3 : 30.84 TP4 : 44.09 SL : If you wish My SL is never a SELL, just an alarm to stop adding money and wait for better dca Follow, Boost, Thank You ! ⚠️ Financial Disclaimer: This post is not financial advice. I am not your financial advisor, your life coach, or your legally responsible adult. Always do your own research and never trade based solely on internet comedy.

$ONCO , Setup ENTRY : CMP TP1 : 0.24 TP2 : 0.48 TP3 : 0.92 TP4 : 1.23 SL : If you wish My SL is never a SELL, just an alarm to stop adding money and wait for better dca Follow, Boost, Thank You ! ⚠️ Financial Disclaimer: This post is not financial advice. I am not your financial advisor, your life coach, or your legally responsible adult. Always do your own research and never trade based solely on internet comedy

BULL ABB - 1100 SEK TARGET ABB is pending right now at 836 SEK and this seems like the bottom for a while. Next target is 1100 SEK, a 31% profit possibility here.

Plejd twords 1400 After a flag and a retest, it should move up towards 1,400. * Increased revenue * New products * Expansion into the industrial market

BEAR ALFA LAVAL - 480 SEK TARGET Alfa Laval is right now pending at 589 SEK and this seems like the top here for a while. So Selling here and buying again at 480 SEK would be a good idea.

BULL EQT 400 SEK TARGET EQT is right now pending at 286 SEK and this seems like the bottom for a while. Next target is somewhere around 400 SEK. A 39% profit possibility here.

$SIVE , Idea SIVE has gone from a prolonged accumulation phase to an explosive markup in just a few months. Moves of this magnitude rarely continue in a straight line, making the current area a key decision point for the coming months. From a Smart Money perspective, price is now testing an important area after reaching fresh highs. The question isn't whether the company is good or bad—it's whether the market needs a reset before the next major move. Scenario 1 – Full Reset The most aggressive scenario is

Potential short Bravida The stock has rallied approximately 63 points since November and now appears due for a healthy pullback and rebalancing. It has also reached a new All-Time High (ATH) while showing declining volume during the final leg higher, followed by a strong bearish rejection. From a technical perspective, there is a high probability that price will retrace to at least Value Area 1 (VA1). Potential profit: 13% Risk-to-Reward (R:R): 1.61

Potential shoort on Volvo soon If Volvo fails to build acceptance above Value Area High (VAH) SEK 354, meaning it cannot hold above this level for an extended period, there is a strong probability of a short opportunity targeting at least SEK 319. This represents a potential gain of approximately 9% or RR 1,45. But if buyers manage to hold the price above the Value Area High (VAH), the stock could continue higher and potentially reach new highs.

Long Potential long at Value Area Low (VAL). Price may briefly dip below to VAL again to retest the level before moving higher. The POC is located below, so I'm placing my stop-loss below the POC

Buy Candidate: EQT AB Idea sourced via technical screener. EQT AB engages in the provision of investment advisory services. The firm operates through the following segments: Private Capital and Real Assets. The Private Capital segment comprises four business lines such as private equity, mid market Asia, ventures and public value. The Real Assets segment comprises two business lines such as infrastructure and real estate. The company was founded by Yngve Conni Jonsson in 1994 and is headquartered in Stockholm, Swede

by Global_Charts

Hold for now The technical indicators say Sell, but there is some way between the channel.

by HailCorkMaster

SBB — Sweden's most shorted stock. Short squeeze setup?SBB_B is once again one of Stockholm's most shorted stocks: ~16% short, ~20 days to cover. If buyers return, the exit door is narrow. What crashed the stock (−90%, from ~68 to ~3)? Not the operations — the balance sheet. SBB was built as a heavily leveraged real-estate giant during the zero-rate years. When rates spiked in 2022, the debt pile became a ticking bomb. Short-seller Viceroy (Feb 2023) attacked its accounting and called it "uninvestable"; S&P cut its rating to junk (May–June 2023,

$SIVE Long OMXSTO:SIVE OTC:SIVEF dropped 70% in 5 weeks. NASDAQ:AAOI just got a positive note this morning: "We view the recent weakness as a buying opportunity as demand remains incredibly strong, supply is constrained and meaningfully below demand, and scale up CPO is a massive content gain opportunity for Optical over multiple years." NASDAQ:AAOI - "We expect AAOI to beat and raise and for 2Q26 to mark a watershed quarter where this starts happening consistently. We believe 2Q26 revenues can

$SIVE , Idea Looking to re-enter around the box area. When (if) it get´s there.

Entering a far more interesting phase than chart first suggest!Cereno Scientific is entering a far more interesting phase now than the chart alone first suggests. After a full year of selling pressure from the 11.90 SEK peak down to the 4.30 SEK low, the stock is no longer just trying to stabilise — it is entering a catalyst-heavy window at the same time as the technical structure is tightening into its main decision zone. That is what makes the setup interesting here. Several things are starting to line up at roughly the same time: momentum is improving, v

by Trueessence31

Senzime – Six Years of Compression, One Decision Point Ahead Senzime is not a confirmed breakout stock yet, but the setup is getting harder to ignore and with an amazing risk reward based on of course profit but the technical, historical and fundamental conditions are very good. After years of drifting, the company has finally started to show real traction: a growing installed base, recurring sensor revenue, improving margins and a stated path toward profitability in 2026. It is still a small-cap medtech name and quarterly numbers can move around, but for

by Trueessence31

$SIVE , SETUP (13/04)Was blocked at Tradingview a few days unable to post any ideas, my mistake. Sorry. ENTRY : CMP ($1.51) TP1 : 3.21 TP2 : 7.57 TP3 : 9.39 TP4 : 12.07 SL : If you wish My SL is never a SELL, just an alarm to stop adding money and wait for better dca Follow, Boost, Thank You ! ⚠️ Financial Disclaimer: This post is not financial advice. I am not your financial advisor, your life coach, or your legally responsible adult. Always do your own research and never trade based solely on internet comed

$SIVE , Idea we´re really doing good on this trade, BUT, I can see OMXSTO:SIVE going to $49 now before completing the pump. Just a possibility, but it can happen.

HNSA - Potential and Conditions for a Full Structural Repricing 250624 - Potential and Conditions for a Full Structural Repricing Hansa Biopharma should no longer be viewed as a standard biotech case driven by news volatility. It is a potential structural repricing case after a multi-year downtrend. Several independent layers are aligning: technical structure, volume regime, event timing, regulatory asymmetry, and a market again willing to react to Hansa-specific catalysts. The backdrop has strengthened as Hansa approaches a second FDA decision, changing t

by Trueessence31

Buy Candidate: Skandinaviska Enskilda Banken AB Idea sourced via technical screener. Skandinaviska Enskilda Banken AB, abbreviated SEB, is a Swedish bank headquartered in Stockholm, Sweden, In Sweden and the Baltic countries, SEB has a full financial service offering.

by Global_Charts

BULL NIBE - 50 SEK Target Nibe is right now pending at 37 SEK. There is a possibility for a 33 SEK target before heading up towards 50 SEK target. There is 35% frofit posibility here. Long term for NIBE is new ATH in near future.

Alzecure Pharma - ACD856 ACD856 (NeuroRestore) is a revolutionary molecule: a positive allosteric modulator (PAM) of Trk receptors. No other known synthetic or natural molecule does this. It is a neurogenesis promoter applicable to neurodegenerative diseases (Alzheimer's, etc.), brain injuries (stroke, etc.), and major depressive disorder (MDD). ALZECURE PHARMA is behind the molecule, which is expected to enter phase 2A clinical trials this year. The company's current market capitalization is only $17 million. They

Free Alvedon Delivery | Uptrend but Weak ## **Price Action & Trend Analysis** The stock has undergone a significant recovery from its February lows (approx. **57.15 SEK** ) and is currently in a transitional phase. * **EMA Structure:** The price is currently trading above the **200-day EMA** (dark blue line). However, the shorter-term averages (20, 50, and 100) are still positioned below the 200 EMA . This "pending" period is a classic consolidation phase where the price needs to hold its ground to pull the faster averages up